June 07, 2022 Asco 2022 – PMV’s therapeutic window slams shut Liver and other toxicities threaten to scupper another attempt to reactivate mutated p53, the “guardian of the genome”.
February 26, 2020 Go or no go? Ozanimod and Fintepla await FDA verdicts Big approval decisions pending in March include ozanimod in multiple sclerosis, where Bristol-Myers is likely to win a green light, while the safety of Zogenix's Fintepla will be scrutinised.
